Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE (ARGX) is a global immunology leader developing antibody-based therapies for rare autoimmune diseases and neuromuscular disorders. This page provides real-time news updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the company’s trajectory.
Investors and industry professionals will find a curated collection of press releases, earnings reports, and partnership announcements. Key focus areas include updates on treatments for myasthenia gravis, CIDP, and thyroid eye disease, alongside innovations like subcutaneous formulations enhancing patient care.
Our repository ensures access to verified developments in ARGX’s clinical pipeline, FDA/EMA interactions, and research collaborations. Content is organized for quick scanning while maintaining scientific accuracy, balancing technical detail with investor-centric insights.
Bookmark this page for streamlined tracking of ARGX’s progress in advancing immunology solutions. Check regularly for authoritative updates on trial results, commercialization efforts, and industry recognition driving the company’s global impact.
argenx (ARGX) announced its third-quarter 2021 financial results, highlighting the build-up of its commercial teams in the U.S. and Japan in preparation for the potential launch of efgartigimod for generalized myasthenia gravis (gMG). The company signed a partnership with Medison for the distribution of efgartigimod in Israel and is pursuing innovative collaborations in key markets. Financially, total operating income rose to $494.6 million due to significant collaboration revenue, while operating losses amounted to $117.8 million. Cash resources increased to $2.53 billion, attributed to a recent global offering.
argenx (ARGX), a global immunology company, will hold a conference call on October 28, 2021, at 2:30 PM CET to discuss its Q3 2021 financial results and offer a business update. The call will be accessible via the Investors section of their website, and a replay will be available for a year. argenx is focused on developing innovative antibody-based therapies for severe autoimmune diseases and cancer, actively evaluating its lead product efgartigimod.
argenx (ARGX) announced additional data from the Phase 3 ADAPT trial of efgartigimod for generalized myasthenia gravis (gMG). Key highlights include consistent depth of response and improvements in disease scores across patient subgroups. Notably, efgartigimod treatment does not impact vaccine immune responses. Initial findings from the MyRealWorld® MG research study shed light on the disease's severity and treatment burden on patients. The data will be showcased at upcoming neuromuscular conferences, enhancing the understanding of efgartigimod's potential benefits.
argenx (Euronext & Nasdaq: ARGX), a global immunology company, has announced its participation in several upcoming conferences focused on healthcare and biotechnology. Key events include the KBC Life Sciences & Biotech Virtual Conference on September 7, the Morgan Stanley Global Healthcare Conference on September 10, the BofA Global Healthcare Conference on September 16, and the SVB Leerink CybeRx Series event on September 22. Further details can be found on the Investors section of argenx's website.
argenx announced the validation of its marketing authorization application (MAA) for efgartigimod as a treatment for generalized myasthenia gravis (gMG) by the European Medicines Agency (EMA). This marks a significant step in the regulatory process, which began on August 19, 2021, with a decision expected by mid-2022. If approved, efgartigimod will be the first FcRn antagonist in Europe. The application is supported by positive results from the Phase 3 ADAPT trial involving 167 patients across North America, Europe, and Japan. The FDA and Japanese authorities are also reviewing the drug.
argenx (Euronext & Nasdaq: ARGX), a global immunology company, announced its participation in a fireside chat at the 2021 Wedbush PacGrow Virtual Healthcare Conference on August 11, 2021, at 11:30 a.m. ET. A live webcast will be available on the argenx website, with a replay accessible for 90 days post-event. The company is dedicated to developing novel antibody-based treatments for serious autoimmune diseases and cancer.
On July 29, 2021, argenx (ARGX) reported a significant increase in revenue, totaling $470.4 million for the first half of 2021, up from $24.7 million in 2020. The company emphasizes its progress with efgartigimod, targeting a December 17, 2021, BLA approval in the U.S. for generalized myasthenia gravis (gMG), and plans to expand its indications. The 'argenx 2025' vision aims for global availability and a comprehensive immunology pipeline. Cash positions rose to $2.73 billion, supported by previous funding and collaborations.
On July 22, 2021, argenx (Euronext & Nasdaq: ARGX) announced a conference call scheduled for July 29, 2021, at 2:30 p.m. CET to discuss its half-year 2021 financial results and provide a business update for the second quarter. The live call will be accessible via the Investors section on the argenx website, with a replay available for a year. argenx focuses on innovative antibody-based therapies for severe autoimmune diseases and cancer, and is actively evaluating multiple candidates in serious indications.
argenx (Euronext & Nasdaq: ARGX) will host a virtual R&D Day on July 20, 2021, at 3:00 p.m. CET (9:00 a.m. ET) to unveil its 'argenx 2025 vision' and update its immunology pipeline. Key announcements include the introduction of new indications for the FcRn antagonist, efgartigimod, alongside Phase 1 data for ARGX-117. The event features expert discussions, including Dr. Rohit Aggarwal and Dr. Russell P. Hall III. A dedicated microsite will host a live webcast and further resources. Access it through the argenx investors' page.
Argentx announced positive results from the Phase 3 ADAPT trial of efgartigimod, a treatment for generalized myasthenia gravis (gMG). The trial showed that 67.7% of patients treated with efgartigimod experienced significant improvement on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to 29.7% in the placebo group (p<0.0001). Efgartigimod is under FDA review with a PDUFA target action date of December 17, 2021. If approved, it would be the first FcRn antagonist for gMG, aiming to improve the quality of life for patients suffering from this debilitating disease.
FAQ
What is the current stock price of Argenx Se (ARGX)?
What is the market cap of Argenx Se (ARGX)?
